admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises...

Why Did the FDA Reject MDMA-Assisted Therapy for PTSD?

Could Psychedelics Transform How Doctors Treat Chronic Pain?

Finding Your Soul’s Purpose: Harnessing Psychedelic Insights for Professional Growth

How to Create Your Own Psychedelic Integration Circle

Real-World Data Reveals Variability in Access to, and Use of, Spravato

The ‘Nada Effect’: Why Psychedelics Don’t Work for Everyone

Psychedelic Outlaws: Cluster Headaches, Citizen Science, and the Story of ClusterBusters

Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps...

The Great Reconnector: Finding Our Way Back Together With Psychedelics

1...91011...218 Page 10 of 218

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic...

Ibogaine – The Promise, the Protocol, and Protecting the Sacred

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin